Shanghai, Aug 24, 2026 — Shanghai’s Medical Procurement Center said it will renew centralized volume-based procurement contracts for selected drugs in the third quarter of 2026, extending agreements with winning manufacturers and their designated distributors after initial purchase volumes were fulfilled.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Shanghai Medical Centralized Bidding and Procurement Affairs Management Center |
| Document | Notice on the Renewal of Selected Drugs in Centralized Procurement (Q3 2026) |
| Effective date | Sept 20, 2026 |
| Scope | Selected drugs with expired procurement agreements and completed contracted volumes |
| Action | Renewal of tripartite purchase agreements among procurement center, winning manufacturers, and designated distributors |
Key Provisions
- Automatic renewal trigger — Contracts are extended for drugs that have reached the end of their initial procurement cycle and satisfied contracted purchase volumes under the volume-based procurement framework.
- Tripartite structure — The procurement center will sign renewed purchase agreements directly with winning enterprises and their appointed distribution partners.
- Complaint channel — Medical institutions are instructed to report any procurement issues to the procurement center during the renewal process.
- Residual compliance — Unspecified matters will be governed by existing centralized procurement regulations and the terms of the tripartite agreements.
Market Impact Analysis
The renewal notice underscores Shanghai’s commitment to maintaining supply continuity under its volume-based procurement regime, a national pricing reform that has slashed drug costs by forcing manufacturers to bid aggressively for hospital market share. By automatically extending contracts for drugs that hit volume targets, regulators are signaling stability to winning suppliers while preventing supply disruptions that could arise from abrupt re-tendering.
For pharmaceutical companies, the renewal mechanism reduces regulatory uncertainty for products that have already secured centralized procurement slots, allowing them to plan production and distribution without navigating fresh bidding rounds. However, the notice also implicitly tightens compliance expectations—manufacturers must have fulfilled contracted volumes to qualify, penalizing those that struggled with supply or quality during the initial term.
Forward-Looking Statement
Industry observers expect the Q3 renewal wave to proceed without major disruption, given that eligible drugs have already demonstrated supply reliability. The Sept 20 effective date aligns with Shanghai’s typical procurement calendar, suggesting seamless transitions for hospital formularies. Looking ahead, the renewal template is likely to be replicated in other provincial procurement platforms as volume-based procurement contracts signed during the 2024-2025 national expansion cycle begin maturing, potentially triggering a broader wave of contract extensions across China’s public hospital network in 2027.-China Health Reform Pulse
For detailed implementation guidelines and the full list of approved products, refer to the official announcements from the Guangdong Provincial Medical Device Exchange Center.
Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/24/24042.shtml